News

Hydrogen water intake improved retinal blood flow (RBF) dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice.

Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.

Ophthalmology Times® talked with Caroline Baumal, MD, about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Japanese investigators have found an ocular biomarker of cardiovascular diseases.

According to data presented at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans, staggered administration of Ixo-vec in non-human primates showed peak aflibercept protein levels in the second eye within the targeted therapeutic range, supporting the potential for bilateral administration.

In a presentation at ARVO 2023 in New Orleans, the company noted data in a nonhuman primate model of non-arteritic anterior ischemic optic neuropathy demonstrates the ability to restore visual function after delivery of a novel gene therapy.

SB15 (Samsung Bioepis) has shown similar efficacy, pharmacokinetics, safety, immunogenicity to aflibercept after 56 Weeks in phase 3 clinical trial.

Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement

The Association for Research in Vision and Ophthalmology (ARVO) kicked off its annual meeting today at the Ernest N. Morial Convention Center in New Orleans.

Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.

Patrick Yu-Wai-Man, MD, PhD, is being recognized by the ARVO Foundation for his research on gene replacement therapy for Leber hereditary optic neuropathy.

Current smokers with Graves' Disease had a greater 5-year cumulative probability, compared with patients who had never smoked, of undergoing orbital decompression.

The endothelial cells play an essential role in vision. They ensure that the cornea remains transparent by keeping it partially dehydrated.

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.

The Iridex PASCAL combines industry-leading speed and precision pattern scanning, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and now, MicroPulse Technology, in an integrated laser platform using half the footprint of its predecessor.

Physicians are using the procedure to treat various stages of the disease.

Researchers from Singapore and Sweden have found a promising stem cell approach to correct photoreceptor cell degeneration, which underlies several forms of visual decline and blindness.

According to the company, the outcomes reported demonstrate a favorable safety profile for its novel, noninvasive glaucoma treatment.

Procedure provides ophthalmologists with another treatment option.

An action filed in U.S. District Court for the Northern District of Illinois by a Pennsylvania woman alleges that neither she nor her physicians were alerted that Tepezza could result in loss of hearing or tinnitus. Horizon said in a statement this and other lawsuits are without merit.

AVA-Net is a deep-learning network developed by scientists from the University of Illinois at Chicago.

The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.